American Century Companies Inc. Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

American Century Companies Inc. raised its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 55.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 160,412 shares of the specialty pharmaceutical company's stock after purchasing an additional 57,406 shares during the quarter. American Century Companies Inc. owned 0.27% of Jazz Pharmaceuticals worth $19,755,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. Lingohr Asset Management GmbH purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $354,000. Teacher Retirement System of Texas grew its position in Jazz Pharmaceuticals by 15.6% during the fourth quarter. Teacher Retirement System of Texas now owns 17,372 shares of the specialty pharmaceutical company's stock valued at $2,139,000 after buying an additional 2,346 shares during the period. Chesapeake Capital Corp IL purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at $376,000. Vinva Investment Management Ltd raised its position in shares of Jazz Pharmaceuticals by 82.7% in the fourth quarter. Vinva Investment Management Ltd now owns 2,897 shares of the specialty pharmaceutical company's stock worth $357,000 after acquiring an additional 1,311 shares during the period. Finally, Xponance Inc. boosted its stake in shares of Jazz Pharmaceuticals by 17.7% during the 4th quarter. Xponance Inc. now owns 7,946 shares of the specialty pharmaceutical company's stock worth $979,000 after acquiring an additional 1,195 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Down 4.4 %

Jazz Pharmaceuticals stock traded down $5.62 during trading on Thursday, reaching $120.82. 1,428,835 shares of the company were exchanged, compared to its average volume of 748,017. The stock's 50 day simple moving average is $132.51 and its two-hundred day simple moving average is $122.91. The company has a market capitalization of $7.34 billion, a P/E ratio of 17.02, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of analyst reports. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Barclays reaffirmed an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Patricia Carr sold 4,813 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,023,305 in the last quarter. Company insiders own 4.20% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.